- Home
- DSGN vs FDMT Comparison
DSGN vs FDMT Comparison
Compare DSGN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGN | FDMT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 515.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DSGN | FDMT |
|---|---|---|
| Price | $12.62 | $9.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $15.25 | ★ $31.71 |
| AVG Volume (30 Days) | 304.9K | ★ 755.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $3.11 | $2.89 |
| 52 Week High | $12.84 | $12.34 |
Technical Indicators
Market Signals| Indicator | DSGN | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 67.34 | 52.29 |
| Support Level | $9.71 | $8.41 |
| Resistance Level | N/A | $10.19 |
| Average True Range (ATR) | 0.58 | 0.69 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 91.34 | 49.59 |
Price Performance
Historical ComparisonAbout DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).